Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 609 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ November 24, 2018 Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma February 15, 2024 Cancer in My Community: Working to Eliminate the Stigma of Cancer... September 14, 2021 Load more HOT NEWS Olaparib Maintenance Fails in Platinum Sensitive Advanced Non-Small Cell Lung Cancer FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated... seven Interesting Facts about Malignant tumors Boy Between the sheets FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years...
